drugset / Trial / NCT00475397

Duloxetine Stress Urinary Incontinence Efficacy and Safety Study

NCT00475397

Phase 3 Completed 120 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

Study F1J-MC-SBBU will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.

Timeline

Start
2003-12
Primary completion
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule